Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Special Re-Pricing of Huge-Seller Drugs “Unacceptable,” JPMA Says on FY2016 Reform
The Japan Pharmaceutical Manufacturers Association (JPMA) issued a statement on December 25, lashing out at the introduction of a special re-pricing rule next April for drugs generating “huge sales.” The statement, issued in the name of JPMA President Masayo Tada,…
To read the full story
Related Article
- Re-Pricing of Huge Seller Drugs “Extremely Unreasonable”: FPMAJ
January 5, 2016
ORGANIZATION
- CES Waivers Could Slow Biosimilar Uptake without Better Communication: Industry
July 23, 2026
- PhRMA Welcomes Honebuto, Prods Japan to Launch Reform This Year
July 22, 2026
- JPMA Backs Honebuto 2026 Innovation Agenda
July 21, 2026
- JPMA, PhRMA Raise Alarm over Generic Approvals During Patent Extensions
July 17, 2026
- WHO Opens Tokyo Hub to Help Health Systems in Developing Nations
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…